We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 4 of 4
Most popular |Most recent


GSK bribery conviction signals increased risks in China

China, USA - October 21 2014 On September 19, 2014, a Chinese court found pharmaceutical giant GlaxoSmithKline PLC (GSK) guilty of bribing doctors and hospitals in order to...

Catherine Kevane, Alexandra P. Grayner.


GlaxoSmithKline and five executives convicted of bribery in China

China, USA - September 24 2014 On Friday, September 19, 2014, a Chinese court found pharmaceutical giant GlaxoSmithKline guilty of bribing doctors and hospitals in order to...

Felix S. Lee, Catherine Kevane, Alexis I. Caloza.


Foreign Corrupt Practices Act (FCPA) guide to preventing improper practices in foreign sales

USA - September 5 2012 The past several years have seen a 400 percent increase in the number of prosecutions under the Foreign Corrupt Practices Act (FCPA), as well as a dramatic increase in the penalties that individuals and corporations must pay to resolve claims....

Catherine Kevane, Susan S. Muck, Tai Lui Tan.


SEC v. Jenkins: SOX 304 clawback requires innocent CEOs and CFOs to return incentive-based compensation if the company restates its financials due to “misconduct”

USA - June 16 2010 In a case of first impression, the United States District Court for the District of Arizona recently ruled that Section 304 of the Sarbanes-Oxley Act of 2002 ("SOX"), the so-called "Clawback Provision," does not require personal misconduct by a company's CEO or CFO to trigger reimbursement obligations after an accounting restatement....

Marie Bafus.